Capricor Therapeutics (CAPR) 10-Q 8 Nov 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 08, 2019
Document and Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Entity Registrant Name	CAPRICOR THERAPEUTICS, INC.
Entity Central Index Key	0001133869
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Trading Symbol	CAPR
Entity Current Reporting Status	Yes
Entity Common Stock, Shares Outstanding		4,246,225
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Shell Company	false
Title of 12(b) Security	Common Stock
Entity Interactive Data Current	Yes

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2019	Dec. 31, 2018
CURRENT ASSETS
Cash and cash equivalents	$ 6,827,570	$ 4,259,266
Marketable securities	0	2,997,150
Restricted cash	232,803	285,831
Grant receivable	101,254	204,868
Prepaid expenses and other current assets	129,161	724,184
TOTAL CURRENT ASSETS	7,290,788	8,471,299
PROPERTY AND EQUIPMENT, net	474,699	574,206
OTHER ASSETS
Intangible assets, net of accumulated amortization of $242,368 and $209,910, respectively	17,314	49,772
Other assets	124,614	151,788
TOTAL ASSETS	7,907,415	9,247,065
CURRENT LIABILITIES
Accounts payable and accrued expenses	947,608	1,148,853
Accounts payable and accrued expenses, related party	13,114	106,366
TOTAL CURRENT LIABILITIES	960,722	1,255,219
LONG-TERM LIABILITIES
CIRM liability	3,376,259	3,376,259
TOTAL LONG-TERM LIABILITIES	3,376,259	3,376,259
TOTAL LIABILITIES	4,336,981	4,631,478
COMMITMENTS AND CONTINGENCIES (NOTE 6)
STOCKHOLDERS' EQUITY
Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding	0	0
Common stock, $0.001 par value, 50,000,000 shares authorized, 4,174,856 and 3,138,748 shares issued and outstanding, respectively	4,175	3,138
Additional paid-in capital	76,477,572	71,338,970
Accumulated other comprehensive income	0	12,393
Accumulated deficit	(72,911,313)	(66,738,914)
TOTAL STOCKHOLDERS' EQUITY	3,570,434	4,615,587
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 7,907,415	$ 9,247,065

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Net of accumulated amortization (in dollars)	$ 242,368	$ 209,910
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common Stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	4,174,856	3,138,748
Common stock, shares outstanding	4,174,856	3,138,748

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
REVENUE
Revenue	$ 142,071	$ 219,249	$ 782,928	$ 1,023,274
OPERATING EXPENSES
Research and development	857,764	3,131,999	4,313,056	9,217,423
General and administrative	911,968	1,259,180	2,720,391	3,826,972
TOTAL OPERATING EXPENSES	1,769,732	4,391,179	7,033,447	13,044,395
LOSS FROM OPERATIONS	(1,627,661)	(4,171,930)	(6,250,519)	(12,021,121)
OTHER INCOME (EXPENSE)
Investment income	21,061	35,792	80,840	89,905
Loss on disposal of fixed asset	0	0	(2,720)	0
NET LOSS	(1,606,600)	(4,136,138)	(6,172,399)	(11,931,216)
OTHER COMPREHENSIVE INCOME (LOSS)
Net unrealized gain (loss) on marketable securities	0	1,922	(12,393)	8,587
COMPREHENSIVE LOSS	$ (1,606,600)	$ (4,134,216)	$ (6,184,792)	$ (11,922,629)
Net loss per share, basic and diluted	$ (0.43)	$ (1.35)	$ (1.76)	$ (4.13)
Weighted average number of shares, basic and diluted	3,746,801	3,060,988	3,500,002	2,886,255

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)	COMMON STOCK [Member]	ADDITIONAL PAID-IN CAPITAL [Member]	OTHER COMPREHENSIVE INCOME (LOSS) [Member]	ACCUMULATED DEFICIT [Member]	Total
Balance at Dec. 31, 2017	$ 2,626	$ 62,760,428	$ 11,620	$ (51,547,819)	$ 11,226,855
Balance (in shares) at Dec. 31, 2017	2,627,049
Issuance of common stock, net of fees	$ 131	2,373,347			2,373,478
Issuance of common stock, net of fees (in shares)	131,178
Stock-based compensation	$ 1	457,611			457,612
Stock-based compensation (in shares)	1,250
Unrealized loss on marketable securities			8,709		8,709
Stock options exercised	$ 38	139,102			139,140
Stock options exercised (in shares)	37,605
Net loss				(3,671,530)	(3,671,530)
Balance at Mar. 31, 2018	$ 2,796	65,730,488	20,329	(55,219,349)	10,534,264
Balance (in shares) at Mar. 31, 2018	2,797,082
Balance at Dec. 31, 2017	$ 2,626	62,760,428	11,620	(51,547,819)	11,226,855
Balance (in shares) at Dec. 31, 2017	2,627,049
Unrealized loss on marketable securities					8,587
Net loss					(11,931,216)
Balance at Sep. 30, 2018	$ 3,074	70,436,176	20,207	(63,479,035)	6,980,422
Balance (in shares) at Sep. 30, 2018	3,074,868
Balance at Mar. 31, 2018	$ 2,796	65,730,488	20,329	(55,219,349)	10,534,264
Balance (in shares) at Mar. 31, 2018	2,797,082
Issuance of common stock, net of fees	$ 201	2,775,198			2,775,399
Issuance of common stock, net of fees (in shares)	200,666
Stock-based compensation	$ 2	446,731			446,733
Stock-based compensation (in shares)	1,666
Unrealized loss on marketable securities			(2,044)		(2,044)
Net loss				(4,123,548)	(4,123,548)
Balance at Jun. 30, 2018	$ 2,999	68,952,417	18,285	(59,342,897)	9,630,804
Balance (in shares) at Jun. 30, 2018	2,999,414
Issuance of common stock, net of fees	$ 75	1,053,326			1,053,401
Issuance of common stock, net of fees (in shares)	75,454
Stock-based compensation		430,433			430,433
Unrealized loss on marketable securities			1,922		1,922
Net loss				(4,136,138)	(4,136,138)
Balance at Sep. 30, 2018	$ 3,074	70,436,176	20,207	(63,479,035)	6,980,422
Balance (in shares) at Sep. 30, 2018	3,074,868
Balance at Dec. 31, 2018	$ 3,138	71,338,970	12,393	(66,738,914)	4,615,587
Balance (in shares) at Dec. 31, 2018	3,138,748
Issuance of common stock, net of fees	$ 228	1,433,059			1,433,287
Issuance of common stock, net of fees (in shares)	227,357
Stock-based compensation		223,166			223,166
Unrealized loss on marketable securities			(12,393)		(12,393)
Net loss				(2,519,345)	(2,519,345)
Balance at Mar. 31, 2019	$ 3,366	72,995,195		(69,258,259)	3,740,302
Balance (in shares) at Mar. 31, 2019	3,366,105
Balance at Dec. 31, 2018	$ 3,138	71,338,970	$ 12,393	(66,738,914)	4,615,587
Balance (in shares) at Dec. 31, 2018	3,138,748
Unrealized loss on marketable securities					(12,393)
Net loss					(6,172,399)
Balance at Sep. 30, 2019	$ 4,175	76,477,572		(72,911,313)	3,570,434
Balance (in shares) at Sep. 30, 2019	4,174,856
Balance at Mar. 31, 2019	$ 3,366	72,995,195		(69,258,259)	3,740,302
Balance (in shares) at Mar. 31, 2019	3,366,105
Issuance of common stock, net of fees	$ 100	543,039			543,139
Issuance of common stock, net of fees (in shares)	100,553
Stock-based compensation		124,217			124,217
Fractional shares eliminated pursuant to reverse stock split		(193)			(193)
Fractional shares eliminated pursuant to reverse stock split (in shares)	(27)
Stock options exercised	$ 1	2,771			2,772
Stock options exercised (in shares)	828
Net loss				(2,046,454)	(2,046,454)
Balance at Jun. 30, 2019	$ 3,467	73,665,029		(71,304,713)	2,363,783
Balance (in shares) at Jun. 30, 2019	3,467,459
Issuance of common stock, net of fees	$ 708	2,587,275			2,587,983
Issuance of common stock, net of fees (in shares)	707,397
Stock-based compensation		225,268			225,268
Unrealized loss on marketable securities					0
Net loss				(1,606,600)	(1,606,600)
Balance at Sep. 30, 2019	$ 4,175	$ 76,477,572		$ (72,911,313)	$ 3,570,434
Balance (in shares) at Sep. 30, 2019	4,174,856

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (6,172,399)	$ (11,931,216)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on disposal of fixed asset	2,720	0
Depreciation and amortization	129,245	114,357
Stock-based compensation	572,651	1,334,778
Change in assets - (increase) decrease:
Receivables	103,614	171,986
Prepaid expenses and other current assets	595,023	74,742
Other assets	27,174	(61,333)
Change in liabilities - increase (decrease):
Accounts payable and accrued expenses	(201,245)	247,537
Accounts payable and accrued expenses, related party	(93,252)	(42,077)
NET CASH USED IN OPERATING ACTIVITIES	(5,036,469)	(10,091,226)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of marketable securities	(15,243)	(15,000,733)
Proceeds from sales and maturities of marketable securities	3,000,000	17,000,000
Purchases of property and equipment	0	(332,081)
NET CASH PROVIDED BY INVESTING ACTIVITIES	2,984,757	1,667,186
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from sale of common stock	4,564,409	6,202,278
Repurchase of fractional shares pursuant to reverse stock split	(193)	0
Proceeds from stock options	2,772	139,140
NET CASH PROVIDED BY FINANCING ACTIVITIES	4,566,988	6,341,418
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH	2,515,276	(2,082,622)
Cash, cash equivalents, and restricted cash balance at beginning of period	4,545,097	6,882,137
Cash, cash equivalents, and restricted cash balance at end of period	7,060,373	4,799,515
SUPPLEMENTAL DISCLOSURES:
Interest paid in cash	0	0
Income taxes paid in cash	$ 0	$ 0

ORGANIZATION AND SUMMARY OF SIG

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2019
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Description of Business Capricor Therapeutics, Inc., a Delaware corporation (referred to herein as “Capricor Therapeutics” or the “Company”), is a clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative cell and exosome-based therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy (“DMD”) and other rare disorders. Capricor, Inc. (“Capricor”), a wholly-owned subsidiary of Capricor Therapeutics, was founded in 2005 as a Delaware corporation based on the innovative work of its founder, Eduardo Marbán, M.D., Ph.D. After completion of a merger between Capricor and a subsidiary of Nile Therapeutics, Inc., a Delaware corporation (“Nile”), on November 20, 2013, Capricor became a wholly-owned subsidiary of Nile and Nile formally changed its name to Capricor Therapeutics, Inc. Capricor Therapeutics, together with its subsidiary, Capricor, have four drug candidates, two of which are in various stages of active development. Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements for Capricor Therapeutics and its wholly-owned subsidiary have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and with the instructions to Form 10‑Q and, therefore, do not include all disclosures necessary for a complete presentation of financial position, results of operations and cash flows in conformity with U.S. GAAP. In the Company’s opinion, all adjustments, consisting of normal and recurring adjustments, considered necessary for a fair presentation have been included. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10‑K, as filed with the Securities and Exchange Commission (the “SEC”) on March 29, 2019, and as amended by the Company’s Amendment No. 1 to Annual Report on Form 10‑K/A filed with the SEC on April 1, 2019, from which the December 31, 2018 consolidated balance sheet has been derived. Interim results are not necessarily indicative of the results that may be expected for the year ending December 31, 2019. Basis of Consolidation Our condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation. Liquidity The Company has historically financed its research and development activities as well as operational expenses from equity financings, government grants, a payment from Janssen Biotech, Inc. (“Janssen”) pursuant to a Collaboration Agreement with Janssen and a loan award and a grant from the California Institute for Regenerative Medicine (“CIRM”). Cash, cash equivalents and marketable securities as of September 30, 2019 were approximately $6.8 million, compared to approximately $7.3 million as of December 31, 2018.The Company has entered into various Common Stock Sales Agreements with H.C. Wainwright & Co. LLC (“Wainwright”) to create at-the-market equity programs under which the Company from time to time offered and sold shares of its common stock, par value $0.001 per share. From October 19, 2017 to September 30, 2019, through the use of these programs, the Company has raised gross proceeds of approximately $14.4 million (see Note 2 - “Stockholders’ Equity”). Additionally, the Company has been awarded various grant and loan awards, which fund, in part, various pre-clinical and clinical activities (see Note 5 – “Government Grant Awards”). As of September 30, 2019, the Company has approximately $0.3 million remaining available under its grants and awards for disbursement, pursuant to the terms of the awards. The Company’s principal uses of cash are for research and development expenses, general and administrative expenses, capital expenditures and other working capital requirements. The Company’s future expenditures and capital requirements may be substantial and will depend on many factors, including, but not limited to, the following: · the timing and costs associated with its clinical trials and pre-clinical studies; · the timing and costs associated with the manufacturing of its product candidates; · the timing and costs associated with commercialization of its product candidates; · the number and scope of its research programs; and · the costs involved in prosecuting and enforcing patent claims and other intellectual property rights. Based on the Company’s current estimates and largely dependent on our decisions with respect to our DMD program, the Company believes it has sufficient cash to fund operations through at least the second quarter of 2020. In the first quarter of 2019, Capricor made certain operational adjustments to reduce expenses by slowing down certain R&D efforts, decreasing headcount, and implementing budget restrictions in order to preserve cash resources which allowed the Company to extend its available cash. Based on the Company’s available cash resources, the Company does not have sufficient cash on hand to support current operations for at least the next twelve months from the date of filing this Report on Form 10-Q. Therefore, there is substantial doubt about the Company’s ability to continue as a going concern. The Company’s options to address its financial position include potentially seeking additional financing primarily from, but not limited to, the sale and issuance of equity or debt securities, the licensing or sale of its technology and other assets, and from government grants. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. The Company will require substantial additional capital to fund its operations. The Company cannot provide assurances that financing will be available when and as needed or that, if available, financing will be available on favorable or acceptable terms. If the Company is unable to obtain additional financing when and if required, it would have a material adverse effect on the Company’s business and results of operations. The Company would likely need to delay, curtail or terminate all or portions of its clinical trial programs. To the extent the Company issues additional equity securities, its existing stockholders would experience substantial dilution. Reverse Stock Split On June 4, 2019, the Company effected a reverse stock split of its outstanding shares of common stock at a ratio of one-for-ten pursuant to a Certificate of Amendment to the Company’s Certificate of Incorporation filed with the Secretary of State of the State of Delaware. The reverse stock split was reflected on the Nasdaq Capital Market (“Nasdaq”) beginning with the opening of trading on June 5, 2019. The primary purpose of the reverse stock split, which was approved by the Company’s stockholders at the Company’s Annual Stockholders Meeting on May 29, 2019, was to enable the Company to regain compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq. Pursuant to the reverse stock split, every ten shares of the Company’s issued and outstanding shares of common stock were automatically combined into one issued and outstanding share of common stock, without any change in the par value per share of the common stock. Unless otherwise indicated, all share and per share amounts of the common stock included in the accompanying condensed consolidated financial statements have been retrospectively adjusted to give effect to the reverse stock split for all periods presented, including reclassifying an amount equal to the reduction in par value to additional paid-in capital. Amounts of common stock resulting from the reverse stock split were rounded down to the nearest whole share and any resulting fractional shares were cancelled for cash. The number of authorized shares of the Company’s common stock remained unchanged. The reverse stock split affected all issued and outstanding shares of the Company’s common stock, and the respective numbers of shares of common stock underlying outstanding stock options, outstanding warrants and the Company’s equity incentive plans were proportionately adjusted. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. The most sensitive estimates relate to the recoverability and fair value of intangible assets and the assumptions used to estimate stock-based compensation expense. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates. Cash, Cash Equivalents, and Restricted Cash The Company considers all highly liquid investments with a maturity of three months or less at the date of purchase to be cash equivalents. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that total the same such amounts shown in the condensed consolidated statements of cash flows. September 30, September 30, 2019 2018 Cash and cash equivalents $ 6,827,570 $ 4,377,797 Restricted cash 232,803 421,718 Total cash, cash equivalents, and restricted cash shown in the statements of cash flows $ 7,060,373 $ 4,799,515 For the nine months ended September 30, 2019, the Company had an outstanding letter of credit for $232,803 as a security deposit for its operating lease agreement for corporate office space (see Note 6 – “Commitments and Contingencies”). The Company is required to maintain this deposit for the duration of the lease agreement and this deposit represents the amount of the Company’s restricted cash for that period. In contrast, for the nine months ended September 30, 2018, restricted cash represents funds received under a CIRM award (the “CIRM Award”) (see Note 5 – “Government Grant Awards”). Restricted cash funds are to be allocated to the research costs as incurred. Generally, a reduction of restricted cash occurs when the Company deems certain costs are attributable to the respective award. Marketable Securities The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company’s marketable securities are considered as available-for-sale and carried at estimated fair values. Realized gains and losses on the sale of debt and equity securities are determined using the specific identification method. Unrealized gains and losses on available-for-sale securities are excluded from net income (loss) and reported in accumulated other comprehensive income (loss) as a separate component of stockholders’ equity. Property and Equipment Property and equipment are stated at cost. Repairs and maintenance costs are expensed in the period incurred. Depreciation is computed using the straight-line method over the related estimated useful life of the asset, which such estimated useful lives range from five to seven years. Leasehold improvements are depreciated on a straight-line basis over the shorter of the useful life of the asset or the lease term. Depreciation was $96,787 and $81,900 for the nine months ended September 30, 2019 and 2018, respectively. Property and equipment, net consisted of the following: September 30, 2019 December 31, 2018 Furniture and fixtures $ 46,709 $ 46,709 Laboratory equipment 931,166 936,480 Leasehold improvements 47,043 47,043 1,024,918 1,030,232 Less accumulated depreciation (550,219) (456,026) Property and equipment, net $ 474,699 $ 574,206 Intangible Assets Amounts attributable to intellectual property consist primarily of the costs associated with the acquisition of certain technologies, patents, pending patents and related intangible assets with respect to research and development activities. Certain intellectual property assets are stated at cost and are amortized on a straight-line basis over the respective estimated useful lives of the assets ranging from five to fifteen years. Total amortization expense was $32,457 for both the nine months ended September 30, 2019 and 2018. A summary of future amortization expense as of September 30, 2019 is as follows: Years ended Amortization Expense 2019 (3 months) 10,819 2020 4,330 2021 2,165 The Company reviews goodwill and intangible assets at least annually for possible impairment. Goodwill and intangible assets are reviewed for possible impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying value. No impairment was recorded for the nine months ended September 30, 2019 and 2018. Revenue Recognition For contracts completed as of December 31, 2017, revenue was recognized in accordance with ASC 605 and other superseded standards. The company applied ASU 606 using the modified retrospective approach for all contracts in process as of January 1, 2018. Government Research Grants Generally, government research grants that provide funding for research and development activities are recognized as income when the related expenses are incurred, as applicable. Because the terms of the CIRM Award allow Capricor to elect to convert the grant into a loan after the end of the project period, the CIRM Award is being classified as a liability rather than income (see Note 5 - “Government Grant Awards”). Grant income is due upon submission of reimbursement request. The transaction price varies for grant income based on the expenses incurred under the awards. Miscellaneous Income Revenue is recognized in connection with the delivery of doses which were developed as part of our past R&D efforts. Income is recorded when the Company has satisfied the obligations as identified in the contracts with the customer (see Note 8 – “Related Party Transactions”). Miscellaneous income is due upon billing. Miscellaneous income is based on contracts with fixed transaction prices. Rent Rent expense for the Company’s leases, which generally have escalating rental amounts over the term of the lease, is recorded on a straight-line basis over the lease term. The difference between the rent expense and rent paid has been recorded as deferred rent in the consolidated balance sheet under accounts payable and accrued expenses. Rent is amortized on a straight-line basis over the term of the applicable lease, without consideration of renewal options. Research and Development Costs relating to the design and development of new products are expensed as research and development as incurred in accordance with Financial Accounting Standards Board (“FASB”) ASC 730-10, Research and Development . Research and development costs amounted to approximately $0.9 million and $3.1 million for the three months ended September 30, 2019 and 2018, respectively, and approximately $4.3 million and $9.2 million for the nine months ended September 30, 2019 and 2018, respectively. Comprehensive Income (Loss) Comprehensive income (loss) generally represents all changes in stockholders’ equity during the period except those resulting from investments by, or distributions to, stockholders. The Company’s comprehensive loss was approximately $1.6 million and $4.1 million for the three months ended September 30, 2019 and 2018, respectively, and approximately $6.2 million and $11.9 million for the nine months ended September 30, 2019 and 2018, respectively. The Company’s other comprehensive income (loss) is related to a net unrealized gain (loss) on marketable securities. For the three months ended September 30, 2019 and 2018, the Company’s other comprehensive gain (loss) was zero and $1,922, respectively. For the nine months ended September 30, 2019 and 2018, the Company’s other comprehensive income (loss) was $(12,393) and $8,587, respectively. Stock-Based Compensation The Company accounts for stock-based employee compensation arrangements in accordance with guidance issued by the FASB, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, consultants, and directors based on estimated fair values. The Company estimates the fair value of stock-based compensation awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s statements of operations. The Company estimates the fair value of stock-based compensation awards using the Black-Scholes model. This model requires the Company to estimate the expected volatility and value of its common stock and the expected term of the stock options, all of which are highly complex and subjective variables. The variables take into consideration, among other things, actual and projected stock option exercise behavior. For employees and directors, the expected life was calculated based on the simplified method as described by the SEC Staff Accounting Bulletin No. 110, Share-Based Payment. For other service providers, the expected life was calculated using the contractual term of the award. The Company's estimate of expected volatility was based on the historical stock price of the Company. The Company has selected a risk-free rate based on the implied yield available on U.S. Treasury securities with a maturity equivalent to the expected term of the options. Loss per Share The Company reports earnings per share in accordance with FSAB ASC 260‑10, Earnings per Share. Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed similarly to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. For the three and nine months ended September 30, 2019 and 2018, warrants and options to purchase were 775,225 and 836,844 shares of common stock, respectively, which have been excluded from the computation of potentially dilutive securities. Potentially dilutive common shares, which primarily consist of stock options issued to employees, consultants, and directors as well as warrants issued, have been excluded from the diluted loss per share calculation because their effect is anti-dilutive. Fair Value Measurements Assets and liabilities recorded at fair value in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair value. The categories are as follows: Level Input: Input Definition: Level I Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date. Level II Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date. Level III Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. The following tables summarize the fair value measurements by level for assets and liabilities measured at fair value on a recurring basis: December 31, 2018 Level I Level II Level III Total Marketable Securities $ 2,997,150 $ — $ — $ 2,997,150 Carrying amounts reported in the balance sheet of cash and cash equivalents, grants receivable, accounts payable and accrued expenses approximate fair value due to their relatively short maturity. The carrying amounts of the Company’s marketable securities are based on market quotations from national exchanges at the balance sheet date. Interest and dividend income are recognized separately on the income statement based on classifications provided by the brokerage firm holding the investments. The fair value of borrowings is not considered to be significantly different from its carrying amount because the stated rates for such debt reflect current market rates and conditions. Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”) , which supersedes existing guidance on accounting for leases in Leases (Topic 840) and issued additional clarification throughout 2018. Under the new guidance, a lessee should recognize assets and liabilities that arise from its leases and disclose qualitative and quantitative information about its leasing arrangements. The Company elected the optional transition method to apply the standard as of January 1, 2019 as the effective date and therefore, did not apply the standard to comparative periods. The Company did not apply the recognition requirements to short-term leases and recognized those lease payments in the Consolidated Statements of Operations and Comprehensive Loss on a straight-line basis over the lease term. The Company also elected the available package of practical expedients in transition which allowed us to not re-assess whether existing or expired arrangements contain a lease, the lease classification of existing or expired leases, or whether previous initial direct costs would qualify for capitalization under the new lease standard. The adoption of this update did not have a material impact on the Company’s financial statements. In June 2018, the FASB issued ASU 2018‑07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting , which simplifies several aspects of the accounting for nonemployee share-based payment transactions resulting from expanding the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The Company early adopted ASU 2018‑07 and all subsequent updates related to this topic on a prospective basis effective July 1, 2018. The adoption of this update did not have a material impact on the Company’s financial statements. In November 2018, the FASB issued ASU 2018‑18, Collaborative Arrangements (Topic 808): clarifying the interaction between Topic 808 and Topic 606. The amendments in the update clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account; adds unit-of-account guidance in Topic 808 to align with the guidance in Topic 606 when an entity is assessing whether the collaborative arrangement or a party of the arrangement is within the scope of Topic 606; requires that in a transaction with a collaborative arrangement participant that is not directly related to sales to third parties, presenting the transaction together with revenue recognized under Topic 606 is precluded if the collaborative arrangement participant is not a customer. The amendments for this update are effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of the new guidance on our consolidated financial statements. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC, did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statement presentation or disclosures.

STOCKHOLDER'S EQUITY

STOCKHOLDER'S EQUITY	9 Months Ended
	Sep. 30, 2019
STOCKHOLDER'S EQUITY
STOCKHOLDER'S EQUITY	2. STOCKHOLDER’S EQUITY Common Stock Sales Agreements Since October 2017, the Company has entered into multiple Common Stock Sales Agreements with Wainwright establishing ATM programs by which Wainwright sold and may continue to sell common stock at the market prices prevailing at the time of sale. Wainwright is entitled to compensation for its services at a commission rate of 3.0% of the gross sales price per share of common stock sold plus reimbursement of certain expenses. These programs are referred to below as the “October 2017 ATM Program,” the “July 2019 ATM Program,” and the “August 2019 ATM Program” based on when each program was initiated. October 2017 ATM Program From October 19, 2017 through expiration of the October 2017 ATM Program on April 23, 2019, the Company sold an aggregate of 899,233 shares at an average price of approximately $13.04 per common share for gross proceeds of approximately $11.7 million. The Company paid 3.0% cash commission on the gross proceeds, plus reimbursement of expenses of Wainwright and legal fees in the aggregate amount of approximately $0.4 million. July 2019 ATM Program From July 22, 2019 through expiration of the July 2019 ATM Program on August 23, 2019, the Company sold an aggregate of 418,450 common shares under the July 2019 ATM Program at an average price of approximately $4.30 per common share for gross proceeds of approximately $1.8 million. The Company paid cash commissions on the gross proceeds, plus reimbursement of expenses of Wainwright and legal fees in the aggregate amount of approximately $0.1 million. August 2019 ATM Program On August 29, 2019, the Company initiated the August 2019 ATM Program. Since August 29, 2019 and through November 8, 2019, the Company has sold an aggregate of 360,316 common shares under the August 2019 ATM Program at an average price of approximately $3.07 per common share for gross proceeds of approximately $1.1 million. The Company paid cash commissions on the gross proceeds, plus reimbursement of expenses of Wainwright and legal fees in the aggregate amount of approximately $0.1 million. Outstanding Shares At September 30, 2019, the Company had 4,174,856 shares of common stock issued and outstanding.

STOCK AWARDS, WARRANTS AND OPTI

STOCK AWARDS, WARRANTS AND OPTIONS	9 Months Ended
	Sep. 30, 2019
STOCK AWARDS, WARRANTS AND OPTIONS
STOCK AWARDS, WARRANTS AND OPTIONS	3. STOCK AWARDS, WARRANTS AND OPTIONS Warrants The following table summarizes all outstanding warrants to purchase shares of the Company’s common stock: Warrants Outstanding December 31, Exercise Price Expiration Grant Date September 30, 2019 2018 per Share Date 3/16/2016 — 84,607 $ 45.00 3/16/2019 — 84,607 Stock Options The Company’s Board of Directors (the “Board”) has approved three stock option plans: (i) the 2006 Stock Option Plan, (ii) the 2012 Restated Equity Incentive Plan (which superseded the 2006 Stock Option Plan) (the “2012 Plan”), and (iii) the 2012 Non-Employee Director Stock Option Plan (the “2012 Non-Employee Director Plan”). At the time the merger between Capricor and Nile became effective, 414,971 shares of common stock were reserved under the 2012 Plan for the issuance of stock options, stock appreciation rights, restricted stock awards and performance unit/share awards to employees, consultants and other service providers. Included in the 2012 Plan are the shares of common stock that were originally reserved under the 2006 Stock Option Plan. Under the 2012 Plan, each stock option granted will be designated in the award agreement as either an incentive stock option or a nonstatutory stock option. Notwithstanding such designation, however, to the extent that the aggregate fair market value of the shares with respect to which incentive stock options are exercisable for the first time by the participant during any calendar year (under all plans of the Company and any parent or subsidiary) exceeds $100,000, such options will be treated as nonstatutory stock options. On June 2, 2016, at the Company’s annual stockholder meeting, the stockholders approved a proposal to amend the 2012 Plan, to, among other things, increase the number of shares of common stock of the Company that may be issued under the 2012 Plan to equal the sum of 414,971 plus 2% of the outstanding shares of common stock as of December 31, 2015, with the number of shares that may be issued under the 2012 Plan automatically increasing thereafter on January 1 of each year, commencing with January 1, 2017, by 2% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year (rounded down to the nearest whole share). As of January 1, 2019, the maximum number of shares that may be issued under the 2012 Plan was 605,595 shares. At the time the merger between Capricor and Nile became effective, 269,731 shares of common stock were reserved under the 2012 Non-Employee Director Plan for the issuance of stock options to members of the Board who are not employees of the Company. Each of the Company’s stock option plans are administered by the Board, or a committee appointed by the Board, which determines the recipients and types of awards to be granted, as well as the number of shares subject to the awards, the exercise price and the vesting schedule. Currently, stock options are granted with an exercise price equal to the closing price of the Company’s common stock on the date of grant, and generally vest over a period of one to four years. The term of stock options granted under each of the plans cannot exceed ten years. The estimated weighted average fair value of the options granted during the three months ended September 30, 2019 and 2018 were approximately $2.73 and $10.53 per share, respectively. The estimated weighted average fair value of the options granted during the nine months ended September 30, 2019 and 2018 were approximately $2.73 and $13.09 per share, respectively. The Company estimates the fair value of each option award using the Black-Scholes option-pricing model. The Company used the following assumptions to estimate the fair value of stock options issued in the nine months ended September 30, 2019 and 2018: September 30, 2019 September 30, 2018 Expected volatility 106% - 128 % 137% - 145 % Expected term 5 - 6 years 5 - 6 years Dividend yield 0 % 0 % Risk-free interest rates 1.4 - 1.6 % 2.3 - 3.0 % Employee and non-employee stock-based compensation expense was as follows: Three months ended September 30, Nine months ended September 30, 2019 2018 2019 2018 General and administrative $ 170,428 $ 283,282 $ 423,318 $ 878,598 Research and development 54,840 147,151 149,333 409,932 Total $ 225,268 $ 430,433 $ 572,651 $ 1,288,530 The Company does not recognize an income tax benefit as the Company believes that an actual income tax benefit may not be realized. For non-qualified stock options, the loss creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance. Common stock, stock options or other equity instruments issued to non-employees (including consultants) as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued. The fair value of stock options is determined using the Black-Scholes option-pricing model. Historically, the Company periodically re-measured the fair value for non-qualified option grants recording an expense over the applicable vesting periods. However, in the third quarter of 2018, the Company early adopted ASU 2018-07. The Company calculates the fair value for non-qualified options as of the date of grant and expenses over the applicable vesting periods. The Company accounts for estimated forfeitures at the date of grant. The following is a schedule summarizing employee and non-employee stock option activity for the nine months ended September 30, 2019: Number of Weighted Average Aggregate Options Exercise Price Intrinsic Value Outstanding at January 1, 2019 701,287 $ 16.18 Granted 130,000 3.20 Exercised (828) 3.35 Expired/Cancelled (75,234) 29.50 Outstanding at September 30, 2019 755,225 $ 12.63 $ 113,682 Exercisable at September 30, 2019 616,462 $ 13.55 $ 67,670 The aggregate intrinsic value represents the difference between the exercise price of the options and the estimated fair value of the Company’s common stock for each of the respective periods. The aggregate intrinsic value of options exercised was approximately $1,987 and $521,678 for the nine months ended September 30, 2019 and 2018, respectively.

CONCENTRATIONS

CONCENTRATIONS	9 Months Ended
	Sep. 30, 2019
CONCENTRATIONS
CONCENTRATIONS	4. CONCENTRATIONS Cash Concentration The Company has historically maintained checking accounts at two financial institutions. These accounts are each insured by the Federal Deposit Insurance Corporation for up to $250,000. Historically, the Company has not experienced any significant losses in such accounts and believes it is not exposed to any significant credit risk on cash, cash equivalents and marketable securities. As of September 30, 2019, the Company maintained approximately $6.6 million of uninsured deposits.

GOVERNMENT GRANT AWARDS

GOVERNMENT GRANT AWARDS	9 Months Ended
	Sep. 30, 2019
GOVERNMENT GRANT AWARDS
GOVERNMENT GRANT AWARDS	5. GOVERNMENT GRANT AWARDS CIRM Grant Award (HOPE) On June 16, 2016, Capricor entered into the CIRM Award with CIRM in the amount of approximately $3.4 million to fund, in part, Capricor’s Phase I/II HOPE-Duchenne clinical trial investigating CAP‑1002 for the treatment of Duchenne muscular dystrophy-associated cardiomyopathy. Pursuant to terms of the CIRM Award, the disbursements were tied to the achievement of specified operational milestones. If CIRM determines, in its sole discretion, that Capricor has not complied with the terms and conditions of the CIRM Award, CIRM may suspend or permanently cease disbursements or pursue other remedies as allowed by law. In addition, the terms of the CIRM Award include a co-funding requirement pursuant to which Capricor is required to spend approximately $2.3 million of its own capital to fund the CIRM funded research project. If Capricor fails to satisfy its co-funding requirement, the amount of the CIRM Award may be proportionately reduced. The CIRM Award is further subject to the conditions and requirements set forth in the CIRM Grants Administration Policy for Clinical Stage Projects. Such requirements include, without limitation, the filing of quarterly and annual reports with CIRM, the sharing of intellectual property pursuant to Title 17, California Code of Regulations (CCR) Sections 100600‑100612, and the sharing with the State of California of a fraction of licensing revenue received from a CIRM funded research project and net commercial revenue from a commercialized product which resulted from the CIRM funded research as set forth in Title 17, CCR Section 100608. The maximum royalty on net commercial revenue that Capricor may be required to pay to CIRM is equal to nine times the total amount awarded and paid to Capricor. After completing the CIRM funded research project and at any time after the award period end date (but no later than the ten year anniversary of the date of the award), Capricor has the right to convert the CIRM Award into a loan, the terms of which will be determined based on various factors, including the stage of the research and development of the program at the time the election is made. On June 20, 2016, Capricor entered into a Loan Election Agreement with CIRM whereby, among other things, CIRM and Capricor agreed that if Capricor elects to convert the grant into a loan, the term of the loan could be up to five years from the date of execution of the applicable loan agreement; provided that the maturity date of the loan will not surpass the ten year anniversary of the grant date of the CIRM Award. Beginning on the date of the loan, the loan shall bear interest on the unpaid principal balance, plus the interest that has accrued prior to the election point according to the terms set forth in CIRM’s Loan Policy (the “New Loan Balance”), at a per annum rate equal to the LIBOR rate for a three-month deposit in U.S. dollars, as published by the Wall Street Journal on the loan date, plus one percent. Interest shall be compounded annually on the outstanding New Loan Balance commencing with the loan date and the interest shall be payable, together with the New Loan Balance, upon the due date of the loan. If Capricor elects to convert the CIRM Award into a loan, certain requirements of the CIRM Award will no longer be applicable, including the revenue sharing requirements. Capricor has not yet made its decision as to whether it will elect to convert the CIRM Award into a loan. Since Capricor may be required to repay some or all of the amounts awarded by CIRM, the Company accounts for this award as a liability rather than income. On August 8, 2017, Capricor entered into an Amendment to the CIRM Notice of Award pursuant to which CIRM approved Capricor’s request to use the remaining estimated project funds of the CIRM Award for technology transfer activities in support of the manufacture of CAP‑1002 to a designated contract manufacturing organization (“CMO”) to help enable Capricor to offer access to CAP‑1002 to patients from the control arm of the HOPE-Duchenne trial via an open-label extension protocol. On September 7, 2018, Capricor entered into an Amendment to the CIRM Notice of Award pursuant to which CIRM added an additional operational milestone which would be satisfied by completion of certain activities related to technology transfer. On January 23, 2019, Capricor entered into an Amendment to the CIRM Notice of Award pursuant to which CIRM added an additional operational milestone which would be satisfied by completion of certain activities related to the HOPE-OLE clinical trial. In 2016, Capricor received $3.1 million under the terms of the CIRM Award. In September 2017, Capricor completed the second operational milestone tied to the last patient completing one year of follow-up, for which approximately $0.3 million was received by Capricor in November 2017. As of September 30, 2019, Capricor’s liability balance for the CIRM Award was $3.4 million. In June 2019, Capricor completed all milestones associated with the CIRM Award and expended all funds received.In the third quarter of 2019, Capricor completed all final close-out documentation associated with this award. NIH Grant Award (HLHS) In September 2016, Capricor was approved for a grant from the National Institutes of Health (“NIH”) to study CAP‑2003 (cardiosphere-derived cell exosomes) for hypoplastic left heart syndrome (HLHS). Under the terms of the NIH grant, Capricor is eligible to receive disbursements in an amount up to approximately $4.2 million, subject to annual and quarterly reporting requirements as well as completion of the study objectives. As of June 30, 2019, approximately $0.7 million had been incurred under the terms of the NIH grant award. In the second quarter of 2019, the award was closed, and all filings completed with no additional expenses expected to be incurred. U.S. Department of Defense Grant Award In September 2016, Capricor was approved for a grant award from the Department of Defense in the amount of approximately $2.4 million to be used toward developing a scalable, commercially-ready process to manufacture CAP‑2003. Under the terms of the award, disbursements will be made to Capricor over a period of approximately three years, subject to annual and quarterly reporting requirements. The Company was granted a no-cost extension until September 29, 2020 to be able to continue to utilize these funds. As of September 30, 2019, approximately $2.1 million has been incurred under the terms of the award.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2019
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	6. COMMITMENTS AND CONTINGENCIES Leases Capricor leases space for its corporate offices from The Bubble Real Estate Company, LLC pursuant to a lease that was originally effective for a two-year period beginning July 1, 2013 with an option to extend the lease for an additional twelve months. Capricor subsequently entered into several amendments extending the term of the lease and modifying its terms. On January 11, 2019, Capricor entered into a Fourth Amendment to Lease (the “Fourth Lease Amendment”) with The Bubble Real Estate Company, LLC. Under the terms of the Fourth Lease Amendment, the lease term extension commenced on January 1, 2019 and will end on December 31, 2019 with a base rent of $25,867 per month. The Company delivered to the landlord an unconditional, irrevocable, transferrable letter of credit effective April 1, 2019 in the amount of $232,803 to cover payments of rent for the remainder of the lease term. We are considering various options with respect to our office lease, which may include, extending our lease period, extending on a month-to-month basis, if possible, or finding a short-term lease in a different location. Capricor leases facilities from Cedars-Sinai Medical Center (“CSMC”) pursuant to a lease (the “Facilities Lease”) that was originally effective for a three-year period beginning June 1, 2014. Capricor has subsequently entered into several amendments extending the term of the lease and modifying its terms. From August 1, 2017 through March 1, 2019, total monthly rent was $19,756. Effective March 1, 2019, the square footage of the leased premises was reduced, resulting in a rent reduction of approximately $4,000 per month. In July 2019, Capricor exercised an option to extend the term of the Facilities Lease for an additional 12-month period through July 31, 2020 with a monthly lease payment of $15,805. The Company has a further option to extend the Facilities Lease through July 31, 2021. In addition, Capricor entered into a month-to-month lease agreement with University Center Lane Tenant, LLC, pursuant to which Capricor leased office space located in San Diego, California. The lease commenced March 1, 2018 and the rental payment was $4,190 per month. The Company terminated the lease effective February 28, 2019. Included within the table below, future minimum rental payments to related parties totaled $158,050. A summary of future minimum rental payments required under operating leases as of September 30, 2019 is as follows: Years ended Operating Leases 2019 (3 months) $ 125,016 2020 $ 110,632 Expenses incurred under operating leases to unrelated parties for the three months ended September 30, 2019 and 2018 were $77,601 and $83,785, respectively, and $239,803 and $244,835 for the nine months ended September 30, 2019 and 2018, respectively. Expenses incurred under operating leases to related parties for each of the three months ended September 30, 2019 and 2018 were $47,415 and $59,268, respectively, and $150,147 and $177,804 for the nine months ended September 30, 2019 and 2018, respectively. Legal Contingencies The Company is not a party to any material legal proceedings at this time. From time to time, the Company may become involved in various legal proceedings that arise in the ordinary course of its business or otherwise. Accounts Payable Over the normal course of business, disputes with vendors may arise. If a vendor dispute payment is probable and able to be estimated, we will record an estimated liability. Employee Severances In the first quarter of 2019, the Board of Directors approved severance packages for all current full-time employees based on length of service and position ranging up to six months of their base salaries subject to certain conditions. No liability has been recorded as of September 30, 2019.

LICENSE AGREEMENTS

LICENSE AGREEMENTS	9 Months Ended
	Sep. 30, 2019
LICENSE AGREEMENTS
LICENSE AGREEMENTS	7. LICENSE AGREEMENTS Capricor’s Technology - CAP‑1002, CAP‑1001, CSps and Exosomes Capricor has entered into exclusive license agreements for intellectual property rights related to certain cardiac-derived cells with Università Degli Studi Di Roma La Sapienza (the “University of Rome”), The Johns Hopkins University (“JHU”) and CSMC. In addition, Capricor has filed patent applications related to the technology developed by its own scientists. University of Rome License Agreement Capricor and the University of Rome entered into a License Agreement, dated June 21, 2006 (the “Rome License Agreement”), which provides for the grant of an exclusive, world-wide, royalty-bearing license by the University of Rome to Capricor (with the right to sublicense) to develop and commercialize licensed products under the licensed patent rights in all fields. Capricor has a right of first negotiation, for a certain period of time, to obtain a license to any new and separate patent applications owned by the University of Rome utilizing cardiac stem cells in cardiac care. Pursuant to the Rome License Agreement, Capricor paid the University of Rome a license issue fee, is currently paying minimum annual royalties in the amount of 20,000 Euros per year, and is obligated to pay a lower-end of a mid-range double-digit percentage on all royalties received as a result of sublicenses granted, which are net of any royalties paid to third parties under a license agreement from such third party to Capricor. The minimum annual royalties are creditable against future royalty payments. The Rome License Agreement will, unless extended or sooner terminated, remain in effect until the later of the last claim of any patent or until any patent application comprising licensed patent rights has expired or been abandoned. Under the terms of the Rome License Agreement, either party may terminate the agreement should the other party become insolvent or file a petition in bankruptcy. Either party may terminate the agreement upon the other party’s material breach, provided that the breaching party will have up to 90 days to cure its material breach. Capricor may also terminate for any reason upon 90 days’ written notice to the University of Rome. The Johns Hopkins University License Agreement Capricor and JHU entered into an Exclusive License Agreement, effective June 22, 2006 (the “JHU License Agreement”), which provides for the grant of an exclusive, world-wide, royalty-bearing license by JHU to Capricor (with the right to sublicense) to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how. In May 2009, the JHU License Agreement was amended to add additional patent rights to the JHU License Agreement in consideration of a payment to JHU and reimbursement of patent costs. Capricor and JHU executed a Second Amendment to the JHU License Agreement, effective as of December 20, 2013, pursuant to which, among other things, certain definitions were added or amended, the timing of certain obligations was revised and other obligations of the parties were clarified. Under the JHU License Agreement, Capricor is required to exercise commercially reasonable and diligent efforts to develop and commercialize licensed products covered by the licenses from JHU. Pursuant to the JHU License Agreement, JHU was paid an initial license fee and, thereafter, Capricor is required to pay minimum annual royalties on the anniversary dates of the JHU License Agreement. The minimum annual royalties range from $5,000 on the first and second anniversary dates to $20,000 on the tenth anniversary date and thereafter. The minimum annual royalties are creditable against a low single-digit running royalty on net sales of products and net service revenues, which Capricor is also required to pay under the JHU License Agreement, which running royalty may be subject to further reduction in the event that Capricor is required to pay royalties on any patent rights to third parties in order to make or sell a licensed product. In addition, Capricor is required to pay a low double-digit percentage of the consideration received by it from sublicenses granted, and is required to pay JHU certain defined development milestone payments upon the successful completion of certain phases of its clinical studies and upon receiving approval from the U.S. Food and Drug Administration (the “FDA”). The development milestones range from $100,000 upon successful completion of a full Phase I clinical study to $1,000,000 upon full FDA market approval and are fully creditable against payments owed by Capricor to JHU on account of sublicense consideration attributable to milestone payments received from a sublicensee. The maximum aggregate amount of milestone payments payable under the JHU License Agreement, as amended, is $1,850,000. In May 2015, Capricor paid the development milestone related to Phase I that was owed to JHU pursuant to the terms of the JHU License Agreement. The JHU License Agreement will, unless sooner terminated, continue in effect in each applicable country until the date of expiration of the last to expire patent within the patent rights, or, if no patents are issued, then for twenty years from the effective date. Under the terms of the JHU License Agreement, either party may terminate the agreement should the other party become insolvent or file a petition in bankruptcy, or fail to cure a material breach within 30 days after notice. In addition, Capricor may terminate for any reason upon 60 days’ written notice. Cedars-Sinai Medical Center License Agreements License Agreement for CDCs On January 4, 2010, Capricor entered into an Exclusive License Agreement with CSMC (the “Original CSMC License Agreement”) for certain intellectual property related to its CDC technology. In 2013, the Original CSMC License Agreement was amended twice resulting in, among other things, a reduction in the percentage of sublicense fees which would have been payable to CSMC. Effective December 30, 2013, Capricor entered into an Amended and Restated Exclusive License Agreement with CSMC (the “Amended CSMC License Agreement”) which amended, restated, and superseded the Original CSMC License Agreement, pursuant to which, among other things, certain definitions were added or amended, the timing of certain obligations was revised and other obligations of the parties were clarified. The Amended CSMC License Agreement provides for the grant of an exclusive, world-wide, royalty-bearing license by CSMC to Capricor (with the right to sublicense) to conduct research using the patent rights and know-how and develop and commercialize products in the field using the patent rights and know-how. In addition, Capricor has the exclusive right to negotiate for an exclusive license to any future rights arising from related work conducted by or under the direction of Dr. Eduardo Marbán on behalf of CSMC. In the event the parties fail to agree upon the terms of an exclusive license for any future rights, Capricor will have a non-exclusive license to such future rights, subject to royalty obligations. Pursuant to the Original CSMC License Agreement, CSMC was paid a license fee and Capricor was obligated to reimburse CSMC for certain fees and costs incurred in connection with the prosecution of certain patent rights. Additionally, Capricor is required to meet certain spending and development milestones. The annual spending requirements ranged from $350,000 to $800,000 each year between 2010 and 2017 (with the exception of 2014, for which there was no annual spending requirement). Pursuant to the Amended CSMC License Agreement, Capricor remains obligated to pay low single-digit royalties on sales of royalty-bearing products as well as a low double-digit percentage of the consideration received from any sublicenses or other grant of rights. The above-mentioned royalties are subject to reduction in the event Capricor becomes obligated to obtain a license from a third party for patent rights in connection with the royalty-bearing product. In 2010, Capricor discontinued its research under some of the patents. The Amended CSMC License Agreement will, unless sooner terminated, continue in effect on a country by country basis until the last to expire of the patents covering the patent rights or future patent rights. Under the terms of the Amended CSMC License Agreement, unless waived by CSMC, the agreement shall automatically terminate: (i) if Capricor ceases, dissolves or winds up its business operations; (ii) in the event of the insolvency or bankruptcy of Capricor or if Capricor makes an assignment for the benefit of its creditors; (iii) if performance by either party jeopardizes the licensure, accreditation or tax exempt status of CSMC or the agreement is deemed illegal by a governmental body; (iv) within 30 days for non-payment of royalties; (v) after 90 days’ notice from CSMC if Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights; (vi) if a material breach has not been cured within 90 days; or (vii) if Capricor challenges any of the CSMC patent rights. If Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights, and fails to cure that breach after 90 days’ notice from CSMC, instead of terminating the license, CSMC has the option to convert any exclusive license to Capricor to a non-exclusive or co-exclusive license. Capricor may terminate the agreement if CSMC fails to cure any material breach within 90 days after notice. On March 20, 2015, Capricor and CSMC entered into a First Amendment to the Amended CSMC License Agreement, pursuant to which the parties agreed to delete certain patent applications from the list of scheduled patents which Capricor determined not to be material to the portfolio. On August 5, 2016, Capricor and CSMC entered into a Second Amendment to the Amended CSMC License Agreement (the “Second License Amendment”), pursuant to which the parties agreed to add certain patent applications to the schedule of patent rights set forth in the agreement. Under the Second License Amendment, (i) the description of scheduled patent rights has been replaced by a revised schedule that includes six additional patent applications; (ii) Capricor paid an upfront fee of $2,500; and (iii) Capricor reimbursed CSMC approximately $10,000 for attorneys’ fees and filing fees that were incurred in connection with the additional patent applications. On December 26, 2017, Capricor entered into a Third Amendment to the Amended CSMC License Agreement thereby amending the CDCs License (the “Third License Amendment”). Under the Third License Amendment, (i) the description of scheduled patent rights has been replaced by a revised schedule that includes seven additional patent applications; and (ii) Capricor is required to reimburse CSMC approximately $50,000 for attorneys’ fees and filing fees that were incurred in connection with the additional patent rights. On June 20, 2018, Capricor and CSMC entered into a Fourth Amendment to the Amended CSMC License Agreement (the “Fourth License Amendment”). Under the Fourth License Amendment, the description of scheduled patent rights has been replaced by a revised schedule that includes two additional patent applications. License Agreement for Exosomes On May 5, 2014, Capricor entered into an Exclusive License Agreement with CSMC (the “Exosomes License Agreement”), for certain intellectual property rights related to exosomes technology. The Exosomes License Agreement provides for the grant of an exclusive, world-wide, royalty-bearing license by CSMC to Capricor (with the right to sublicense) in order to conduct research using the patent rights and know-how and to develop and commercialize products in the field using the patent rights and know-how. In addition, Capricor has the exclusive right to negotiate for an exclusive license to any future rights arising from related work conducted by or under the direction of Dr. Eduardo Marbán on behalf of CSMC. In the event the parties fail to agree upon the terms of an exclusive license, Capricor shall have a non-exclusive license to such future rights, subject to royalty obligations. Pursuant to the Exosomes License Agreement, CSMC was paid a license fee and Capricor reimbursed CSMC for certain fees and costs incurred in connection with the preparation and prosecution of certain patent applications. Additionally, Capricor is required to meet certain non-monetary development milestones and is obligated to pay low single-digit royalties on sales of royalty-bearing products as well as a single-digit percentage of the consideration received from any sublicenses or other grant of rights. The above-mentioned royalties are subject to reduction in the event Capricor becomes obligated to obtain a license from a third party for patent rights in connection with the royalty bearing product. The Exosomes License Agreement will, unless sooner terminated, continue in effect on a country by country basis until the last to expire of the patents covering the patent rights or future patent rights. Under the terms of the Exosomes License Agreement, unless waived by CSMC, the agreement shall automatically terminate: (i) if Capricor ceases, dissolves or winds up its business operations; (ii) in the event of the insolvency or bankruptcy of Capricor or if Capricor makes an assignment for the benefit of its creditors; (iii) if performance by either party jeopardizes the licensure, accreditation or tax exempt status of CSMC or the agreement is deemed illegal by a governmental body; (iv) within 30 days for non-payment of royalties; (v) after 90 days if Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights; (vi) if a material breach has not been cured within 90 days; or (vii) if Capricor challenges any of the CSMC patent rights. If Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights, and fails to cure that breach after 90 days’ notice from CSMC, instead of terminating the license, CSMC has the option to convert any exclusive license to Capricor to a non-exclusive or co-exclusive license. Capricor may terminate the agreement if CSMC fails to cure any material breach within 90 days after notice. On February 27, 2015, Capricor and CSMC entered into a First Amendment to Exosomes License Agreement (the “First Exosomes License Amendment”). Under the First Exosomes License Amendment, (i) the description of scheduled patent rights has been replaced by a revised schedule that includes four additional patent applications; (ii) Capricor was required to pay CSMC an upfront fee of $20,000; (iii) Capricor was required to reimburse CSMC approximately $34,000 for attorneys’ fees and filing fees that were incurred in connection with the additional patent rights; and (iv) Capricor is required to pay CSMC certain defined product development milestone payments upon reaching certain phases of its clinical studies and upon receiving approval for a product from the FDA. The product development milestones range from $15,000 upon the dosing of the first patient in a Phase I clinical trial of a product to $75,000 upon receipt of FDA approval for a product. The maximum aggregate amount of milestone payments payable under the Exosomes License Agreement, as amended, is $190,000. On June 10, 2015, Capricor and CSMC entered into a Second Amendment to Exosomes License Agreement, thereby amending the Exosomes License Agreement further to add an additional patent application to the Schedule of Patent Rights. On August 5, 2016, Capricor and CSMC entered into a Third Amendment to the Exosomes License Agreement (the “Third Exosomes License Amendment”), pursuant to which the parties agreed to add certain patent applications to the schedule of patent rights under the agreement. Under the Third Exosomes License Amendment, (i) the description of scheduled patent rights has been replaced by a revised schedule that includes three additional patent applications; (ii) Capricor paid CSMC an upfront fee of $2,500; and (iii) Capricor reimbursed CSMC approximately $16,000 for attorneys’ fees and filing fees that were incurred in connection with the additional patent applications. On December 26, 2017, Capricor and CSMC entered into a Fourth Amendment to Exosomes License Agreement, thereby amending the Exosomes License (the “Fourth Exosomes License Amendment”). Under the Fourth Exosomes License Amendment, (i) the description of scheduled patent rights was replaced by a revised schedule that includes seven additional patent applications; (ii) Capricor is required to reimburse CSMC approximately $50,000 for attorneys’ fees and filing fees that were incurred in connection with the additional patent rights; and (iii) a schedule to the Exosomes License was modified to extend the milestone deadline for filing an IND for at least one product to December 31, 2018. On June 20, 2018, Capricor and CSMC entered into a Fifth Amendment to the Exosomes License Agreement (the “Fifth License Amendment”). Under the Fifth License Amendment, (i) the description of scheduled patent rights has been replaced by a revised schedule that includes four additional patent applications; and (ii) Capricor is required to reimburse CSMC approximately $27,000 for attorneys’ fees and filing fees that were incurred in connection with the additional patent rights. On September 25, 2018, Capricor and CSMC entered into a Sixth Amendment to the Exosomes License Agreement (the “Sixth License Amendment”). Under the Sixth License Amendment, the milestone deadline for filing an IND for at least one product has been extended to December 31, 2019. If the Company does not file an IND by December 31, 2019, or negotiate an additional extension of the milestone deadline, CSMC would have the option to convert the exclusive license to a non-exclusive license or to a co-exclusive license or terminate the license under Title 35, Section 203 of the United States Code. Prior to exercising such option, Capricor has the opportunity to cure the failure to file an IND for a period of 90 days after its receipt of written notice from CSMC of its intent to exercise its option.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2019
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS	8. RELATED PARTY TRANSACTIONS Lease and Sub-Lease Agreement As noted above, Capricor is a party to lease agreements with CSMC, which holds more than 5% of the outstanding capital stock of Capricor Therapeutics (see Note 6 – “Commitments and Contingencies”), and CSMC has served as an investigative site in Capricor’s clinical trials. Additionally, Dr. Eduardo Marbán, who holds more than 5% of the outstanding capital stock of Capricor Therapeutics and participates as an observer at the Company’s meetings of the Board of Directors, is the Director of the Cedars-Sinai Smidt Heart Institute, a co-founder of Capricor and the Chairman of the Company’s Scientific Advisory Board. On April 1, 2013, Capricor entered into a sublease with Reprise Technologies, LLC, a limited liability company which is wholly owned by Dr. Frank Litvack, the Company’s Executive Chairman and member of its Board of Directors, for $2,500 per month. The sublease is on a month-to-month basis. For each of the three months periods ended September 30, 2019 and 2018, Capricor recognized $7,500 in sublease income from the related party. For each of the nine month periods ended September 30, 2019 and 2018, Capricor recognized $22,500 in sublease income from the related party. Sublease income is recorded as a reduction to general and administrative expenses. Consulting Agreements In 2013, Capricor entered into a Consulting Agreement with Dr. Frank Litvack, the Company’s Executive Chairman and a member of its Board of Directors, whereby Capricor agreed to pay Dr. Litvack $10,000 per month for consulting services. The agreement is terminable upon 30 days’ notice. Payables to Related Party At September 30, 2019 and December 31, 2018, the Company had accounts payable and accrued expenses to related parties totaling $13,114 and $106,366, respectively. CSMC accounts for $13,114 and $100,191 of the total accounts payable and accrued expenses to related parties as of September 30, 2019 and December 31, 2018, respectively. CSMC expenses relate to research and development costs. During the nine months ended September 30, 2019 and 2018, the Company paid CSMC approximately $288,000 and $570,000, respectively, for such costs. Related Party Clinical Trials Capricor has agreed to provide cells for investigational purposes in two clinical trials sponsored by CSMC. These cells were developed as part of the Company’s past research and development efforts. The first trial is known as “Regression of Fibrosis and Reversal of Diastolic Dysfunction in HFpEF Patients Treated with Allogeneic CDCs.” Dr. Eduardo Marbán is the named principal investigator under the study. The second trial is known as “Pulmonary Arterial Hypertension treated with Cardiosphere-derived Allogeneic Stem Cells.” In both studies, Capricor will provide the necessary number of doses of cells and will receive a negotiated amount of monetary compensation which is estimated to be approximately $2.1 million over several years. For the three months ended September 30, 2019 and 2018, the Company recognized approximately $41,000 and $47,000, respectively, as revenue. For the nine months ended September 30, 2019 and 2018, the Company recognized approximately $324,000 and $257,000, respectively, as revenue. As of September 30, 2019, and December 31, 2018, approximately $8,000 and $269,000, respectively, is outstanding and recorded in prepaid expenses and other current assets. Related Party Agreement On May 10, 2018, Capricor and TrialTech Medical, Inc., a corporation in which Dr. Frank Litvack, our Executive Chairman and a director, is a co-founder, shareholder and chairman, entered into an agreement whereby TrialTech Medical, Inc. would provide clinical trial services to Capricor for its HOPE‑2 clinical trial. In December 2018, Capricor ceased the use of those services. Total costs incurred under the agreement were approximately $42,600.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2019
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	9. SUBSEQUENT EVENTS Additional Sales Under August 2019 ATM Program Subsequent to September 30, 2019 and through November 8, 2019, the Company sold an aggregate of 71,369 common shares under the August 2019 ATM Program at an average price of approximately $2.96 per common share for gross proceeds of approximately $0.2 million. The Company paid cash commissions on the gross proceeds, plus reimbursement of expenses of the placement agent and legal fees in the aggregate amount of approximately $7,500.

ORGANIZATION AND SUMMARY OF S_2

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2019
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Description of Business	Description of Business Capricor Therapeutics, Inc., a Delaware corporation (referred to herein as “Capricor Therapeutics” or the “Company”), is a clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative cell and exosome-based therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy (“DMD”) and other rare disorders. Capricor, Inc. (“Capricor”), a wholly-owned subsidiary of Capricor Therapeutics, was founded in 2005 as a Delaware corporation based on the innovative work of its founder, Eduardo Marbán, M.D., Ph.D. After completion of a merger between Capricor and a subsidiary of Nile Therapeutics, Inc., a Delaware corporation (“Nile”), on November 20, 2013, Capricor became a wholly-owned subsidiary of Nile and Nile formally changed its name to Capricor Therapeutics, Inc. Capricor Therapeutics, together with its subsidiary, Capricor, have four drug candidates, two of which are in various stages of active development.
Basis of Presentation	Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements for Capricor Therapeutics and its wholly-owned subsidiary have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and with the instructions to Form 10‑Q and, therefore, do not include all disclosures necessary for a complete presentation of financial position, results of operations and cash flows in conformity with U.S. GAAP. In the Company’s opinion, all adjustments, consisting of normal and recurring adjustments, considered necessary for a fair presentation have been included. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10‑K, as filed with the Securities and Exchange Commission (the “SEC”) on March 29, 2019, and as amended by the Company’s Amendment No. 1 to Annual Report on Form 10‑K/A filed with the SEC on April 1, 2019, from which the December 31, 2018 consolidated balance sheet has been derived. Interim results are not necessarily indicative of the results that may be expected for the year ending December 31, 2019.
Basis of Consolidation	Basis of Consolidation Our condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.
Liquidity	Liquidity The Company has historically financed its research and development activities as well as operational expenses from equity financings, government grants, a payment from Janssen Biotech, Inc. (“Janssen”) pursuant to a Collaboration Agreement with Janssen and a loan award and a grant from the California Institute for Regenerative Medicine (“CIRM”). Cash, cash equivalents and marketable securities as of September 30, 2019 were approximately $6.8 million, compared to approximately $7.3 million as of December 31, 2018.The Company has entered into various Common Stock Sales Agreements with H.C. Wainwright & Co. LLC (“Wainwright”) to create at-the-market equity programs under which the Company from time to time offered and sold shares of its common stock, par value $0.001 per share. From October 19, 2017 to September 30, 2019, through the use of these programs, the Company has raised gross proceeds of approximately $14.4 million (see Note 2 - “Stockholders’ Equity”). Additionally, the Company has been awarded various grant and loan awards, which fund, in part, various pre-clinical and clinical activities (see Note 5 – “Government Grant Awards”). As of September 30, 2019, the Company has approximately $0.3 million remaining available under its grants and awards for disbursement, pursuant to the terms of the awards. The Company’s principal uses of cash are for research and development expenses, general and administrative expenses, capital expenditures and other working capital requirements. The Company’s future expenditures and capital requirements may be substantial and will depend on many factors, including, but not limited to, the following: · the timing and costs associated with its clinical trials and pre-clinical studies; · the timing and costs associated with the manufacturing of its product candidates; · the timing and costs associated with commercialization of its product candidates; · the number and scope of its research programs; and · the costs involved in prosecuting and enforcing patent claims and other intellectual property rights. Based on the Company’s current estimates and largely dependent on our decisions with respect to our DMD program, the Company believes it has sufficient cash to fund operations through at least the second quarter of 2020. In the first quarter of 2019, Capricor made certain operational adjustments to reduce expenses by slowing down certain R&D efforts, decreasing headcount, and implementing budget restrictions in order to preserve cash resources which allowed the Company to extend its available cash. Based on the Company’s available cash resources, the Company does not have sufficient cash on hand to support current operations for at least the next twelve months from the date of filing this Report on Form 10-Q. Therefore, there is substantial doubt about the Company’s ability to continue as a going concern. The Company’s options to address its financial position include potentially seeking additional financing primarily from, but not limited to, the sale and issuance of equity or debt securities, the licensing or sale of its technology and other assets, and from government grants. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. The Company will require substantial additional capital to fund its operations. The Company cannot provide assurances that financing will be available when and as needed or that, if available, financing will be available on favorable or acceptable terms. If the Company is unable to obtain additional financing when and if required, it would have a material adverse effect on the Company’s business and results of operations. The Company would likely need to delay, curtail or terminate all or portions of its clinical trial programs. To the extent the Company issues additional equity securities, its existing stockholders would experience substantial dilution.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. The most sensitive estimates relate to the recoverability and fair value of intangible assets and the assumptions used to estimate stock-based compensation expense. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.
Cash, Cash Equivalents, and Restricted Cash	Cash, Cash Equivalents, and Restricted Cash The Company considers all highly liquid investments with a maturity of three months or less at the date of purchase to be cash equivalents. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that total the same such amounts shown in the condensed consolidated statements of cash flows. September 30, September 30, 2019 2018 Cash and cash equivalents $ 6,827,570 $ 4,377,797 Restricted cash 232,803 421,718 Total cash, cash equivalents, and restricted cash shown in the statements of cash flows $ 7,060,373 $ 4,799,515 For the nine months ended September 30, 2019, the Company had an outstanding letter of credit for $232,803 as a security deposit for its operating lease agreement for corporate office space (see Note 6 – “Commitments and Contingencies”). The Company is required to maintain this deposit for the duration of the lease agreement and this deposit represents the amount of the Company’s restricted cash for that period. In contrast, for the nine months ended September 30, 2018, restricted cash represents funds received under a CIRM award (the “CIRM Award”) (see Note 5 – “Government Grant Awards”). Restricted cash funds are to be allocated to the research costs as incurred. Generally, a reduction of restricted cash occurs when the Company deems certain costs are attributable to the respective award.
Marketable Securities	Marketable Securities The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company’s marketable securities are considered as available-for-sale and carried at estimated fair values. Realized gains and losses on the sale of debt and equity securities are determined using the specific identification method. Unrealized gains and losses on available-for-sale securities are excluded from net income (loss) and reported in accumulated other comprehensive income (loss) as a separate component of stockholders’ equity.
Property and Equipment	Property and Equipment Property and equipment are stated at cost. Repairs and maintenance costs are expensed in the period incurred. Depreciation is computed using the straight-line method over the related estimated useful life of the asset, which such estimated useful lives range from five to seven years. Leasehold improvements are depreciated on a straight-line basis over the shorter of the useful life of the asset or the lease term. Depreciation was $96,787 and $81,900 for the nine months ended September 30, 2019 and 2018, respectively. Property and equipment, net consisted of the following: September 30, 2019 December 31, 2018 Furniture and fixtures $ 46,709 $ 46,709 Laboratory equipment 931,166 936,480 Leasehold improvements 47,043 47,043 1,024,918 1,030,232 Less accumulated depreciation (550,219) (456,026) Property and equipment, net $ 474,699 $ 574,206
Intangible Assets	Intangible Assets Amounts attributable to intellectual property consist primarily of the costs associated with the acquisition of certain technologies, patents, pending patents and related intangible assets with respect to research and development activities. Certain intellectual property assets are stated at cost and are amortized on a straight-line basis over the respective estimated useful lives of the assets ranging from five to fifteen years. Total amortization expense was $32,457 for both the nine months ended September 30, 2019 and 2018. A summary of future amortization expense as of September 30, 2019 is as follows: Years ended Amortization Expense 2019 (3 months) 10,819 2020 4,330 2021 2,165 The Company reviews goodwill and intangible assets at least annually for possible impairment. Goodwill and intangible assets are reviewed for possible impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying value. No impairment was recorded for the nine months ended September 30, 2019 and 2018.
Revenue Recognition	Revenue Recognition For contracts completed as of December 31, 2017, revenue was recognized in accordance with ASC 605 and other superseded standards. The company applied ASU 606 using the modified retrospective approach for all contracts in process as of January 1, 2018. Government Research Grants Generally, government research grants that provide funding for research and development activities are recognized as income when the related expenses are incurred, as applicable. Because the terms of the CIRM Award allow Capricor to elect to convert the grant into a loan after the end of the project period, the CIRM Award is being classified as a liability rather than income (see Note 5 - “Government Grant Awards”). Grant income is due upon submission of reimbursement request. The transaction price varies for grant income based on the expenses incurred under the awards. Miscellaneous Income Revenue is recognized in connection with the delivery of doses which were developed as part of our past R&D efforts. Income is recorded when the Company has satisfied the obligations as identified in the contracts with the customer (see Note 8 – “Related Party Transactions”). Miscellaneous income is due upon billing. Miscellaneous income is based on contracts with fixed transaction prices.
Rent	Rent Rent expense for the Company’s leases, which generally have escalating rental amounts over the term of the lease, is recorded on a straight-line basis over the lease term. The difference between the rent expense and rent paid has been recorded as deferred rent in the consolidated balance sheet under accounts payable and accrued expenses. Rent is amortized on a straight-line basis over the term of the applicable lease, without consideration of renewal options.
Research and Development	Research and Development Costs relating to the design and development of new products are expensed as research and development as incurred in accordance with Financial Accounting Standards Board (“FASB”) ASC 730-10, Research and Development . Research and development costs amounted to approximately $0.9 million and $3.1 million for the three months ended September 30, 2019 and 2018, respectively, and approximately $4.3 million and $9.2 million for the nine months ended September 30, 2019 and 2018, respectively.
Comprehensive Income (Loss)	Comprehensive Income (Loss) Comprehensive income (loss) generally represents all changes in stockholders’ equity during the period except those resulting from investments by, or distributions to, stockholders. The Company’s comprehensive loss was approximately $1.6 million and $4.1 million for the three months ended September 30, 2019 and 2018, respectively, and approximately $6.2 million and $11.9 million for the nine months ended September 30, 2019 and 2018, respectively. The Company’s other comprehensive income (loss) is related to a net unrealized gain (loss) on marketable securities. For the three months ended September 30, 2019 and 2018, the Company’s other comprehensive gain (loss) was zero and $1,922, respectively. For the nine months ended September 30, 2019 and 2018, the Company’s other comprehensive income (loss) was $(12,393) and $8,587, respectively.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based employee compensation arrangements in accordance with guidance issued by the FASB, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, consultants, and directors based on estimated fair values. The Company estimates the fair value of stock-based compensation awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s statements of operations. The Company estimates the fair value of stock-based compensation awards using the Black-Scholes model. This model requires the Company to estimate the expected volatility and value of its common stock and the expected term of the stock options, all of which are highly complex and subjective variables. The variables take into consideration, among other things, actual and projected stock option exercise behavior. For employees and directors, the expected life was calculated based on the simplified method as described by the SEC Staff Accounting Bulletin No. 110, Share-Based Payment. For other service providers, the expected life was calculated using the contractual term of the award. The Company's estimate of expected volatility was based on the historical stock price of the Company. The Company has selected a risk-free rate based on the implied yield available on U.S. Treasury securities with a maturity equivalent to the expected term of the options.
Loss per Share	Loss per Share The Company reports earnings per share in accordance with FSAB ASC 260‑10, Earnings per Share. Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed similarly to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. For the three and nine months ended September 30, 2019 and 2018, warrants and options to purchase were 775,225 and 836,844 shares of common stock, respectively, which have been excluded from the computation of potentially dilutive securities. Potentially dilutive common shares, which primarily consist of stock options issued to employees, consultants, and directors as well as warrants issued, have been excluded from the diluted loss per share calculation because their effect is anti-dilutive.
Fair Value Measurements	Fair Value Measurements Assets and liabilities recorded at fair value in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair value. The categories are as follows: Level Input: Input Definition: Level I Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date. Level II Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date. Level III Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. The following tables summarize the fair value measurements by level for assets and liabilities measured at fair value on a recurring basis: December 31, 2018 Level I Level II Level III Total Marketable Securities $ 2,997,150 $ — $ — $ 2,997,150 Carrying amounts reported in the balance sheet of cash and cash equivalents, grants receivable, accounts payable and accrued expenses approximate fair value due to their relatively short maturity. The carrying amounts of the Company’s marketable securities are based on market quotations from national exchanges at the balance sheet date. Interest and dividend income are recognized separately on the income statement based on classifications provided by the brokerage firm holding the investments. The fair value of borrowings is not considered to be significantly different from its carrying amount because the stated rates for such debt reflect current market rates and conditions.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”) , which supersedes existing guidance on accounting for leases in Leases (Topic 840) and issued additional clarification throughout 2018. Under the new guidance, a lessee should recognize assets and liabilities that arise from its leases and disclose qualitative and quantitative information about its leasing arrangements. The Company elected the optional transition method to apply the standard as of January 1, 2019 as the effective date and therefore, did not apply the standard to comparative periods. The Company did not apply the recognition requirements to short-term leases and recognized those lease payments in the Consolidated Statements of Operations and Comprehensive Loss on a straight-line basis over the lease term. The Company also elected the available package of practical expedients in transition which allowed us to not re-assess whether existing or expired arrangements contain a lease, the lease classification of existing or expired leases, or whether previous initial direct costs would qualify for capitalization under the new lease standard. The adoption of this update did not have a material impact on the Company’s financial statements. In June 2018, the FASB issued ASU 2018‑07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting , which simplifies several aspects of the accounting for nonemployee share-based payment transactions resulting from expanding the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The Company early adopted ASU 2018‑07 and all subsequent updates related to this topic on a prospective basis effective July 1, 2018. The adoption of this update did not have a material impact on the Company’s financial statements. In November 2018, the FASB issued ASU 2018‑18, Collaborative Arrangements (Topic 808): clarifying the interaction between Topic 808 and Topic 606. The amendments in the update clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account; adds unit-of-account guidance in Topic 808 to align with the guidance in Topic 606 when an entity is assessing whether the collaborative arrangement or a party of the arrangement is within the scope of Topic 606; requires that in a transaction with a collaborative arrangement participant that is not directly related to sales to third parties, presenting the transaction together with revenue recognized under Topic 606 is precluded if the collaborative arrangement participant is not a customer. The amendments for this update are effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of the new guidance on our consolidated financial statements. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC, did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statement presentation or disclosures.

ORGANIZATION AND SUMMARY OF S_3

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2019
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Schedule of Cash And Cash Equivalents And Restricted Cash	The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that total the same such amounts shown in the condensed consolidated statements of cash flows. September 30, September 30, 2019 2018 Cash and cash equivalents $ 6,827,570 $ 4,377,797 Restricted cash 232,803 421,718 Total cash, cash equivalents, and restricted cash shown in the statements of cash flows $ 7,060,373 $ 4,799,515
Schedule of Property, Plant And Equipment	Property and equipment, net consisted of the following: September 30, 2019 December 31, 2018 Furniture and fixtures $ 46,709 $ 46,709 Laboratory equipment 931,166 936,480 Leasehold improvements 47,043 47,043 1,024,918 1,030,232 Less accumulated depreciation (550,219) (456,026) Property and equipment, net $ 474,699 $ 574,206
Schedule of Future Amortization Expense	A summary of future amortization expense as of September 30, 2019 is as follows: Years ended Amortization Expense 2019 (3 months) 10,819 2020 4,330 2021 2,165
Schedule of Fair Value Measurements	The following tables summarize the fair value measurements by level for assets and liabilities measured at fair value on a recurring basis: December 31, 2018 Level I Level II Level III Total Marketable Securities $ 2,997,150 $ — $ — $ 2,997,150

STOCK AWARDS, WARRANTS AND OP_2

STOCK AWARDS, WARRANTS AND OPTIONS (Tables)	9 Months Ended
	Sep. 30, 2019
Text Block [Abstract]
Schedule of Outstanding Warrants	The following table summarizes all outstanding warrants to purchase shares of the Company’s common stock: Warrants Outstanding December 31, Exercise Price Expiration Grant Date September 30, 2019 2018 per Share Date 3/16/2016 — 84,607 $ 45.00 3/16/2019 — 84,607
Schedule of Fair Value of Option Using Black-Scholes option	The Company estimates the fair value of each option award using the Black-Scholes option-pricing model. The Company used the following assumptions to estimate the fair value of stock options issued in the nine months ended September 30, 2019 and 2018: September 30, 2019 September 30, 2018 Expected volatility 106% - 128 % 137% - 145 % Expected term 5 - 6 years 5 - 6 years Dividend yield 0 % 0 % Risk-free interest rates 1.4 - 1.6 % 2.3 - 3.0 %
Schedule of Employee and Non-Employee Stock based Compensation expense	Employee and non-employee stock-based compensation expense was as follows: Three months ended September 30, Nine months ended September 30, 2019 2018 2019 2018 General and administrative $ 170,428 $ 283,282 $ 423,318 $ 878,598 Research and development 54,840 147,151 149,333 409,932 Total $ 225,268 $ 430,433 $ 572,651 $ 1,288,530
Schedule of Employee and Non-Employee Stock Option	The following is a schedule summarizing employee and non-employee stock option activity for the nine months ended September 30, 2019: Number of Weighted Average Aggregate Options Exercise Price Intrinsic Value Outstanding at January 1, 2019 701,287 $ 16.18 Granted 130,000 3.20 Exercised (828) 3.35 Expired/Cancelled (75,234) 29.50 Outstanding at September 30, 2019 755,225 $ 12.63 $ 113,682 Exercisable at September 30, 2019 616,462 $ 13.55 $ 67,670

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	9 Months Ended
	Sep. 30, 2019
COMMITMENTS AND CONTINGENCIES
Schedule of Future Minimum Rental Payments	A summary of future minimum rental payments required under operating leases as of September 30, 2019 is as follows: Years ended Operating Leases 2019 (3 months) $ 125,016 2020 $ 110,632

ORGANIZATION AND SUMMARY OF S_4

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2018	Dec. 31, 2017
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Cash and cash equivalents	$ 6,827,570	$ 4,259,266	$ 4,377,797
Restricted cash	232,803	285,831	421,718
Total cash, cash equivalents, and restricted cash shown in the statements of cash flows	$ 7,060,373	$ 4,545,097	$ 4,799,515	$ 6,882,137

ORGANIZATION AND SUMMARY OF S_5

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Property, Plant and Equipment, Gross	$ 1,024,918	$ 1,030,232
Less accumulated depreciation	(550,219)	(456,026)
Property and equipment, net	474,699	574,206
Furniture and fixtures [Member]
Property, Plant and Equipment, Gross	46,709	46,709
Laboratory equipment [Member]
Property, Plant and Equipment, Gross	931,166	936,480
Leasehold improvements [Member]
Property, Plant and Equipment, Gross	$ 47,043	$ 47,043

ORGANIZATION AND SUMMARY OF S_6

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets (Details)	Sep. 30, 2019USD ($)
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
2019 (3 months)	$ 10,819
2020	4,330
2021	$ 2,165

ORGANIZATION AND SUMMARY OF S_7

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair Value Measurements (Details)	Dec. 31, 2018USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable Securities	$ 2,997,150
Level I [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable Securities	2,997,150
Level II [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable Securities	0
Level III [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable Securities	$ 0

ORGANIZATION AND SUMMARY OF S_8

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)	Aug. 23, 2019USD ($)$ / sharesshares	Jun. 04, 2019	Apr. 23, 2019USD ($)$ / sharesshares	Sep. 30, 2019USD ($)$ / shares	Mar. 31, 2019USD ($)	Sep. 30, 2018USD ($)	Jun. 30, 2018USD ($)	Mar. 31, 2018USD ($)	Sep. 30, 2019USD ($)$ / sharesshares	Sep. 30, 2018USD ($)shares	Sep. 30, 2019USD ($)$ / shares	Dec. 31, 2018USD ($)$ / shares	Oct. 19, 2017$ / shares
Accounting Policies [Line Items]
Common Stock, Par or Stated Value Per Share | $ / shares				$ 0.001					$ 0.001		$ 0.001	$ 0.001
Research and Development Expense				$ 857,764		$ 3,131,999			$ 4,313,056	$ 9,217,423
Cash, Cash Equivalents, and Marketable Securities				6,800,000					6,800,000		$ 6,800,000	$ 7,300,000
Comprehensive Income (Loss), Net of Tax, Attributable to Parent				(1,606,600)		(4,134,216)			(6,184,792)	(11,922,629)
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax				0	$ (12,393)	$ 1,922	$ (2,044)	$ 8,709	(12,393)	8,587
Amortization of Intangible Assets									32,457	32,457
Depreciation									96,787	81,900
Proceeds from Issuance of Common Stock									4,564,409	$ 6,202,278
Reverse stock split ratio		0.10
Amount Available Under Grant Awards				300,000					$ 300,000		300,000
Warrant [Member]
Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares									775,225	836,844
October 2017 ATM Program [Member]
Accounting Policies [Line Items]
Common Stock, Par or Stated Value Per Share | $ / shares													$ 0.001
Stock Issued During Period, Shares, New Issues | shares			899,233
Shares Issued, Price Per Share | $ / shares			$ 13.04
Proceeds from Issuance of Common Stock			$ 11,700,000								14,400,000
July 2019 ATM Program [Member]
Accounting Policies [Line Items]
Stock Issued During Period, Shares, New Issues | shares	418,450
Shares Issued, Price Per Share | $ / shares	$ 4.30
Proceeds from Issuance of Common Stock	$ 1,800,000
Letter of Credit [Member]
Accounting Policies [Line Items]
Security deposit for its operating lease agreement				$ 232,803					$ 232,803		$ 232,803
Minimum [Member]
Accounting Policies [Line Items]
Estimated useful lives (in years)									5 years
Minimum [Member] | Intellectual Property [Member]
Accounting Policies [Line Items]
Intangible assets, useful lives (in years)									5 years
Maximum [Member]
Accounting Policies [Line Items]
Estimated useful lives (in years)									7 years
Maximum [Member] | Intellectual Property [Member]
Accounting Policies [Line Items]
Intangible assets, useful lives (in years)									15 years

STOCKHOLDER'S EQUITY (Details)

STOCKHOLDER'S EQUITY (Details) - USD ($)	Aug. 23, 2019	Apr. 23, 2019	Nov. 08, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Dec. 31, 2018
Class of Stock [Line Items]
Common Stock, Shares, Outstanding				4,174,856		4,174,856	3,138,748
Proceeds from Issuance of Common Stock				$ 4,564,409	$ 6,202,278
October 2017 ATM Program [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues		899,233
Payments of Stock Issuance Costs		$ 400,000
Shares Issued, Price Per Share		$ 13.04
Proceeds from Issuance of Common Stock		$ 11,700,000				$ 14,400,000
Commission Rate On Sale Price Per Share		3.00%
July 2019 ATM Program [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues	418,450
Payments of Stock Issuance Costs	$ 100,000
Shares Issued, Price Per Share	$ 4.30
Proceeds from Issuance of Common Stock	$ 1,800,000
August 2019 ATM Program [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues			360,316
Payments of Stock Issuance Costs			$ 100,000
Shares Issued, Price Per Share			$ 3.07
Proceeds from Issuance of Common Stock			$ 1,100,000

STOCK AWARDS, WARRANTS AND OP_3

STOCK AWARDS, WARRANTS AND OPTIONS - Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Sep. 30, 2019
Class of Warrant or Right [Line Items]
Warrants Outstanding	84,607	0
Period Issuance One [Member]
Class of Warrant or Right [Line Items]
Warrants Outstanding	84,607	0
Exercise Price per Share	$ 45
Expiration Date	Mar. 16, 2019

STOCK AWARDS, WARRANTS AND OP_4

STOCK AWARDS, WARRANTS AND OPTIONS - Assumptions (Details)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	128.00%	145.00%
Expected term	6 years	6 years
Risk-free interest rates	1.60%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	106.00%	137.00%
Expected term	5 years	5 years
Risk-free interest rates	1.40%

STOCK AWARDS, WARRANTS AND OP_5

STOCK AWARDS, WARRANTS AND OPTIONS - Stock-based Compensation Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation cost	$ 225,268	$ 430,433	$ 572,651	$ 1,288,530
General and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation cost	170,428	283,282	423,318	878,598
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation cost	$ 54,840	$ 147,151	$ 149,333	$ 409,932

STOCK AWARDS, WARRANTS AND OP_6

STOCK AWARDS, WARRANTS AND OPTIONS - Stock Option Activity (Details) - Stock Option [Member]	9 Months Ended
	Sep. 30, 2019USD ($)$ / sharesshares
Number of Options
Outstanding at Beginning of the period | shares	701,287
Granted | shares	130,000
Exercised | shares	(828)
Expired/Cancelled | shares	(75,234)
Outstanding at Ending of the period | shares	755,225
Exercisable | shares	616,462
Weighted Average Exercise Price
Outstanding at Beginning of the period | $ / shares	$ 16.18
Granted | $ / shares	3.20
Exercised | $ / shares	3.35
Expired/Cancelled | $ / shares	29.50
Outstanding at Ending of the period | $ / shares	12.63
Exercisable | $ / shares	$ 13.55
Aggregate Intrinsic Value
Outstanding | $	$ 113,682
Exercisable | $	$ 67,670

STOCK AWARDS, WARRANTS AND OP_7

STOCK AWARDS, WARRANTS AND OPTIONS - Additional Information (Details) - USD ($)	Jun. 02, 2016	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2017	Jan. 01, 2019
Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 2.73	$ 10.53	$ 2.73	$ 13.09
Amount Authorized in Plans After Merger						414,971
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value				$ 1,987	$ 521,678
Stock Option Plan 2012 [Member]
Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Line Items]
Share-based Compensation Arrangement By Share-based Payment Award, Percentage Of Annual Increase In Number Of Shares Authorized						2.00%
Maximum number of common stock reserved under the Plan							605,595
Non-Employee Director Plan 2012 [Member]
Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Line Items]
Amount Authorized in Plans After Merger		269,731		269,731
Stock Option [Member] | Stock Option Plan 2012 [Member]
Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Line Items]
Amount Authorized in Plans After Merger		414,971		414,971
Share-based Compensation Arrangement By Share-based Payment Award, Percentage Of Annual Increase In Number Of Shares Authorized	2.00%
Incentive Stock Option [Member] | Stock Option Plan 2012 [Member]
Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Line Items]
Minimum Limit Of Fair Market Value To Be Treated As Non-Statutory Stock				$ 100,000

CONCENTRATIONS (Details)

CONCENTRATIONS (Details)	Sep. 30, 2019USD ($)
Concentration Risk [Line Items]
Cash, Uninsured Amount	$ 6,600,000
Financial Institution One [Member]
Concentration Risk [Line Items]
Cash, FDIC Insured Amount	$ 250,000

GOVERNMENT GRANT AWARDS (Detail

GOVERNMENT GRANT AWARDS (Details) - USD ($) $ in Millions	Jun. 30, 2019	Jun. 16, 2016	Sep. 30, 2019	Nov. 30, 2017	Dec. 31, 2016	Sep. 30, 2016
Disbursement Amount Under Grant Award				$ 0.3	$ 3.1
California Institute for Regenerative Medicine [Member]
Grant Award Liability		$ 3.4	$ 3.4
Minimum Expected Contribution		$ 2.3
NIH Grant Award HLHS [Member]
Maximum Amount Approved for Grant Award						$ 4.2
Cost Incurred Under Award	$ 0.7
U.S. Department of Defense Grant Award [Member]
Approved For Grant Award						$ 2.4
Cost Incurred Under Award			$ 2.1

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Future Minimum Rental Payments (Details)	Sep. 30, 2019USD ($)
COMMITMENTS AND CONTINGENCIES
2019 (3 months)	$ 125,016
2020	$ 110,632

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended	9 Months Ended		12 Months Ended	20 Months Ended
	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Jun. 30, 2019	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2019	Mar. 31, 2019	Jul. 31, 2019	Jan. 11, 2019
Commitments and Contingencies Disclosure [Line Items]
Operating Leases, Rent Expense								$ 19,756
Operating Leases, Rent Expense, Minimum Rentals	$ 4,190
Leases Monthly Payments For Additional Twelve Months									$ 15,805
Lessor, Operating Lease, Term of Contract									12 months
Guarantees, Fair Value Disclosure										$ 232,803
Scenario, Forecast [Member]
Commitments and Contingencies Disclosure [Line Items]
Operating Leases, Rent Expense							$ 25,867
Monthly Lease Payment [Member]
Commitments and Contingencies Disclosure [Line Items]
Operating Leases, Rent Expense, Contingent Rentals				$ 4,000
Unrelated Party [Member]
Commitments and Contingencies Disclosure [Line Items]
Operating Leases, Rent Expense, Net		$ 77,601	$ 83,785		$ 239,803	$ 244,835
Related party [Member]
Commitments and Contingencies Disclosure [Line Items]
Operating Leases, Rent Expense		47,415	$ 59,268		150,147	$ 177,804
Operating Leases, Future Minimum Payments Due		$ 158,050			$ 158,050

LICENSE AGREEMENTS (Details)

LICENSE AGREEMENTS (Details)	Dec. 26, 2017USD ($)	Aug. 05, 2016USD ($)	Jun. 20, 2018USD ($)	Dec. 26, 2017USD ($)	Feb. 27, 2015USD ($)	Sep. 30, 2019EUR (€)	Sep. 30, 2019USD ($)
LICENSE AGREEMENTS [Line Items]
Payments for Royalties | €						€ 20,000
Upfront Payment		$ 2,500
Reimbursed Expenses to be Paid				$ 50,000
Written Notice Period						90 days	90 days
CSMC [Member]
LICENSE AGREEMENTS [Line Items]
Upfront Payment		2,500
Reimbursed Expenses to be Paid	$ 50,000	16,000
Exosomes License Agreement [Member]
LICENSE AGREEMENTS [Line Items]
Upfront Payment					$ 20,000
Additional Milestone Payment					190,000
Reimbursed Expenses to be Paid			$ 27,000		34,000
CSMC License Agreement [Member]
LICENSE AGREEMENTS [Line Items]
Reimbursed Expenses to be Paid		$ 10,000
Minimum [Member]
LICENSE AGREEMENTS [Line Items]
Payments for Royalties							$ 5,000
Development Milestones							350,000
Maximum [Member]
LICENSE AGREEMENTS [Line Items]
Payments for Royalties							20,000
Development Milestones							800,000
Maximum [Member] | JHU License Agreement [Member]
LICENSE AGREEMENTS [Line Items]
Potential Milestone Payments							1,850,000
Completion of Phase One [Member] | Exosomes License Agreement [Member]
LICENSE AGREEMENTS [Line Items]
Milestone Payments To Be Made Upon Successful Completion Of Certain Phases					15,000
Completion of Phase One [Member] | Minimum [Member]
LICENSE AGREEMENTS [Line Items]
Range of Milestone Payments, Payable Upon Successful Completion of Certain Phases							100,000
Obtention of FDA Approval [Member] | Exosomes License Agreement [Member]
LICENSE AGREEMENTS [Line Items]
Milestone Payments To Be Made Upon Successful Completion Of Certain Phases					$ 75,000
Obtention of FDA Approval [Member] | Maximum [Member]
LICENSE AGREEMENTS [Line Items]
Range of Milestone Payments, Payable Upon Successful Completion of Certain Phases							$ 1,000,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
	Mar. 24, 2014	Apr. 30, 2013	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Related Party Transaction [Line Items]
Accounts Payable and Accrued Expenses Related Party Current			$ 13,114		$ 13,114		$ 106,366
Related Party Transaction, Other Revenues from Transactions with Related Party			$ 41,000	$ 47,000	324,000	$ 257,000
Payments for Reimbursement for Research and Development Expenses Incurred Related Party					288,000	570,000
Compensation Receivable In Connection to Services to be Provided					2,100,000
Cost For Clinical Trial Services					$ 42,600
Dr Eduardo Marban [Member]
Related Party Transaction [Line Items]
Ownership percentage held			5.00%		5.00%
CSMC [Member]
Related Party Transaction [Line Items]
Ownership percentage held			5.00%		5.00%
Prepaid Expenses and Other Current Assets [Member]
Related Party Transaction [Line Items]
Due to Related Parties			$ 8,000		$ 8,000		269,000
Board of Directors Chairman [Member] | Sublease Agreement with Frank Litvack [Member]
Related Party Transaction [Line Items]
Rental Income, Nonoperating		$ 2,500	7,500	$ 7,500	22,500	$ 22,500
Board of Directors Chairman [Member] | Consulting Agreement with Frank Litvack [Member]
Related Party Transaction [Line Items]
Monthly Consulting Fees to Related Party	$ 10,000
Affiliated Entity [Member] | Transaction other than Sub-Award Agreement [Member]
Related Party Transaction [Line Items]
Accounts Payable and Accrued Expenses Related Party Current			$ 13,114		$ 13,114		$ 100,191

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - USD ($)	Nov. 08, 2019	Nov. 08, 2019	Sep. 30, 2019	Sep. 30, 2018
Proceeds from Issuance of Common Stock			$ 4,564,409	$ 6,202,278
August 2019 ATM Program [Member]
Stock Issued During Period, Shares, New Issues		360,316
Shares Issued, Price Per Share	$ 3.07	$ 3.07
Proceeds from Issuance of Common Stock		$ 1,100,000
Payments of Stock Issuance Costs		$ 100,000
Subsequent Event [Member] | August 2019 ATM Program [Member]
Stock Issued During Period, Shares, New Issues	71,369
Shares Issued, Price Per Share	$ 2.96	$ 2.96
Proceeds from Issuance of Common Stock	$ 200,000
Payments of Stock Issuance Costs	$ 7,500